AZRX Share Price | First Wave Biopharma, Inc. Stock Analysis & Recommendation

Q: How big is First Wave Biopharma, Inc.?

Market Cap: As of Jun 18, First Wave Biopharma, Inc. has a market capitalization of 2.24 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -22.34 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 57.80 million, while total assets were reported at 85.41 million.

Q: What does First Wave Biopharma, Inc. do?

Overview: First Wave Biopharma, Inc. is a clinical development-stage biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of gastrointestinal disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 2.24 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.01 Return on Equity: -39.54% Price to Book: 0.04Contact Details: Address: 1615 SOUTH CONGRESS AVENUE, SUITE 103, DELRAY BEACH FL : 33445 Tel: 1 646 6997855 Website: https://www.azurrx.com/

Q: Is First Wave Biopharma, Inc. overvalued or undervalued?

As of 5 October 2023, First Wave Biopharma, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%. In comparison to its peers, such as Amgen with a price-to-earnings ratio of 15.2 and Gilead Sciences at 11.0, First Wave Biopharma presents a more favorable valuation. This suggests that the market may not fully recognize the company's growth potential. Recent stock performance has also shown resilience against the Sensex, reinforcing the notion that the stock is undervalued relative to its fundamentals.

Q: Is First Wave Biopharma, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for First Wave Biopharma, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view, particularly in the weekly MACD, Bollinger Bands, KST, and OBV, all of which are bullish. The daily moving averages also confirm a bullish trend. However, the monthly RSI indicates bearishness, which suggests some caution. In terms of performance, the stock has shown impressive returns, with a 1-year return of 350.98% compared to the S&P 500's 17.14%, and a year-to-date return of 146.52% against the S&P 500's 12.22%. Overall, the technical indicators point to a bullish outlook, albeit with some mixed signals in the monthly timeframe.

Results Declared: First Wave Biopharma, Inc. has declared results on 01 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

63.71 k

Shareholding (Dec 2025)

FII

0.03%

Held by 3 FIIs

DII

99.2%

Held by 1 DIIs

Promoter

0.00%

How big is First Wave Biopharma, Inc.?

22-Jun-2025

As of Jun 18, First Wave Biopharma, Inc. has a market capitalization of 2.24 million, with net sales of 0.00 million and a net profit of -22.34 million over the last four quarters. The company's shareholder's funds are 57.80 million, and total assets are 85.41 million.

View full answer

What does First Wave Biopharma, Inc. do?

22-Jun-2025

First Wave Biopharma, Inc. is a clinical development-stage biopharmaceutical company focused on non-systemic biologics for gastrointestinal disorders. It has a market cap of $2.24 million and reported a net profit loss of $1 million for Q1 2025.

View full answer

Who are in the management team of First Wave Biopharma, Inc.?

22-Jun-2025

As of March 2022, the management team of First Wave Biopharma, Inc. includes Mr. Edward Borkowski (Independent Chairman), Mr. James Sapirstein (President and CEO), and four Independent Directors: Mr. Charles Casamento, Mr. Gregory Oakes, Dr. Alastair Riddell, and Dr. Vern Schramm. They oversee the company's strategic direction and operations.

View full answer

Is First Wave Biopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, First Wave Biopharma, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%, outperforming peers like Amgen and Gilead Sciences.

View full answer

Is First Wave Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, First Wave Biopharma, Inc. shows a bullish trend supported by strong technical indicators, despite some caution from the monthly RSI, with a remarkable 1-year return of 350.98% compared to the S&P 500's 17.14%.

View full answer

Compare First Wave Biopharma, Inc. with Similar Stocks

Histogen, Inc.Aditxt, Inc.Phio Pharmaceuticals Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.02

Return on Equity

-26.49%

Price to Book

0.09

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.53%

6 Months

-12.31%

1 Year

185.93%

2 Years

-58.99%

3 Years

18.75%

4 Years

-99.93%

5 Years

-100.0%

First Wave Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

10.69%

EBIT to Interest (avg)

-22.30

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

14.60%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.09

EV to EBIT

-1.76

EV to EBITDA

-1.76

EV to Capital Employed

0.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-4.36%

ROE (Latest)

-26.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.77%)

Foreign Institutions

Held by 3 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 69.49% vs -187.80% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-1.20",
          "chgp": "-241.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-11.80",
          "chgp": "69.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-129,331.60%",
          "val2": "0.00%",
          "chgp": "-12,933.16%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 60.26% vs 1.27% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.50",
          "val2": "-15.60",
          "chgp": "58.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-15.60",
          "chgp": "60.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-195,399.80%",
          "val2": "0.00%",
          "chgp": "-19,539.98%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.10

-1.20

-241.67%

Interest

0.40

0.00

Exceptional Items

-0.10

0.00

Consolidate Net Profit

-3.60

-11.80

69.49%

Operating Profit Margin (Excl OI)

-129,331.60%

0.00%

-12,933.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 69.49% vs -187.80% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.50

-15.60

58.33%

Interest

0.50

0.00

Exceptional Items

-0.10

0.00

Consolidate Net Profit

-6.20

-15.60

60.26%

Operating Profit Margin (Excl OI)

-195,399.80%

0.00%

-19,539.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 60.26% vs 1.27% in Dec 2024

All Annual Results

Company CV

About First Wave Biopharma, Inc.

First Wave Biopharma, Inc.

Pharmaceuticals & Biotechnology

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Company Coordinates

Company Details

1615 SOUTH CONGRESS AVENUE, SUITE 103 , DELRAY BEACH FL : 33445

Tel: 1 646 6997855

https://www.azurrx.com/

Registrar Details